Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyPreventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyA phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium reportEnhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.Genomically Incorporated 5-Fluorouracil that Escapes UNG-Initiated Base Excision Repair Blocks DNA Replication and Activates Homologous RecombinationOvarian cancer: in search of better marker systems based on DNA repair defectsATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous LeukemiaHELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events.DNA damage repair in ovarian cancer: unlocking the heterogeneity.
P2860
Q26745673-563F2471-D357-40DF-8E15-A716596D7D70Q28084568-EEDBC598-8EF2-4290-A47D-22C4EB46D2B0Q33415790-4E0B3A78-24FF-40CA-A5C3-67B542E20E31Q33709593-FDE58357-8EFF-4A73-A087-CE8FD349FC15Q35246419-9CAE3802-03D4-4CCE-8ADA-B41DC379C512Q36432422-A32F77CA-2DBF-4B59-9023-1952AA1C56E4Q36589947-70EA3703-9C05-4FBD-AB3C-D959C608798DQ36941455-DF5BBAF5-84B3-4E6E-ABC6-D352B8116DE8Q37100102-E3B841EE-5388-4321-A55D-1DFAE6AB5A4DQ37331571-2C0D7E5F-8148-4475-915B-C3CD038F2095Q37691597-16C57D52-1722-4E47-9BAA-FC88175CF2DBQ42130288-F6889FAD-D8E7-4222-8E13-3F9FE3B242B4Q42315217-D33A4683-4CE3-4815-85C8-22E3AE3495FFQ47652095-8160A213-B9A2-4AC7-AE59-11084F0F2E6BQ48333916-9042221C-F30E-471C-9AD4-966EC48FD261Q55399645-D45A8E3B-BC95-491C-8F64-4904FA10AA6A
P2860
Identification of DNA repair pathways that affect the survival of ovarian cancer cells treated with a poly(ADP-ribose) polymerase inhibitor in a novel drug combination.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Identification of DNA repair p ...... r in a novel drug combination.
@ast
Identification of DNA repair p ...... r in a novel drug combination.
@en
type
label
Identification of DNA repair p ...... r in a novel drug combination.
@ast
Identification of DNA repair p ...... r in a novel drug combination.
@en
prefLabel
Identification of DNA repair p ...... r in a novel drug combination.
@ast
Identification of DNA repair p ...... r in a novel drug combination.
@en
P2093
P2860
P356
P1476
Identification of DNA repair p ...... r in a novel drug combination.
@en
P2093
Amelia M Huehls
Catherine J Huntoon
Jill M Wagner
Larry M Karnitz
P2860
P304
P356
10.1124/MOL.112.080614
P577
2012-07-25T00:00:00Z